Table 1:

Baseline demographics and cancer treatment history for included patients (n=37)

	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Cohort 5	Expansion Cohort	Overall n (%)
Dose of Ipafricept (Q3W)	5 mg/kg n (%)	10 mg/kg n (%)	2 mg/kg n (%)	4 mg/kg n (%)	6 mg/kg n (%)	6 mg/kg n (%)
Patients Enrolled	3	4	8	9	6	7	37
	3 (100.0)	4 (100.0)	8 (100.0)	9 (100.0)	6 (100.0)	7 (100.0)	37 (100.0)
Demographics
Age
Mean(SD)	57.7 (9.6)	58.8(11.4)	57.5(8.6)	60(10.8)	59.8(11.5)	61.7(7.3)	59.4(9.24)
Median	56	55.5	56	59	60.5	63	59
Ethnicity
Hispanic or Latino	0	0	0	0	0	1(14.3%)	1(2.7%)
Not Hispanic or Latino	3(100%)	4(100%)	8(100%)	9(100%)	6(100%)	6(85.7%)	36(97.3%)
Race
American Indian or Alaskan Native	0	1(25%)	0	0	0	0	1(2.7%)
Black or African American	0	0	1(12.5%)	1(11.1%)	0	1(14.3%)	3(8.1%)
White	3(100%)	3(75%)	7(87.5%)	8(88.9%)	6(100%)	6(85.7%)	33(39.2%)
BMI (kg/m2) mean (SD)	26.7(5.7)	32.1(8.7)	29.1(6.8)	30.6(4.6)	29.7(4.0)	26.1(3.3)	29.1(5.4)
Cancer History
Time since diagnosis (mos)
Mean (SD)	23.1 (5.7)	26 (17.2)	35.5 (14.4)	24.9 (16.8)	23 (13.9)	27.8(22.4)	27.4(16.1)
Median	23.2	33.5	30.8	19	27	19.8	26
Histology
Serous	3(100%)	4(100%)	8(100%)	7(77.8%)	3(50%)	5(71.4%)	30(81.1%)
Adenocarcinoma NOS				0	2(33.3%)	1(14.3%)	3(8.1%)
Other				2(22.2%)	1(16.7%)	1(14.3%)	4(10.8%)
Prior Lines of Therapy
1 Regimen	3(100%)	4(100%)	4(50%)	5(55.6%)	3(50%)	4(57.2%)	23(62.2%)
2 Regimens			2(25%)	1(11.1%)	3(50%)	1(14.3%)	7(18.9%)
3 Regimens			1(12.5%)	2(22.2%)		0	3(8.1%)
>3 Regimens			1(12.5%)	1(11.1%)		2(28.6%)	4(10.8%)

SD= standard deviation, NOS = not otherwise specified; mos = months